Medicare Enrolled

Dr. Sanford Chen, M.D.

Ophthalmology · Santa Ana, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Consulting-driven
1200 N TUSTIN AVE, Santa Ana, CA 92705
7149728235
In practice since 2005 (20 years)
NPI: 1427051994 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Chen from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chen? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Chen

Dr. Sanford Chen is an ophthalmology specialist in Santa Ana, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Chen performed 25,561 Medicare services across 3,748 unique beneficiaries.

Between the years covered by Open Payments, Dr. Chen received a total of $108,654 from 40 pharmaceutical and/or device companies across 608 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Chen is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 4% volume in CA $108,654 industry payments

Medicare Practice Summary

Medicare Utilization ↗
25,561
Medicare services
Top 4% in CA for ophthalmology
3,748
Unique beneficiaries
$108
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,278 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Eye injection (Vabysmo/faricimab)
An injection of faricimab-svoa, a medication administered in 0.1 mg doses.
13,020 $29 $50
Extended eye exam with retinal drawing
A detailed examination of the back of the eye that includes creating a drawing of the retina.
2,419 $20 $90
Retinal imaging (OCT scan)
This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye.
2,351 $33 $155
Aflibercept eye injection (Eylea) 2,146 $693 $1,051
Eye injection for retinal disease
A procedure involving the administration of medication directly into the eye.
1,600 $97 $1,100
Comprehensive eye exam, established patient
A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider.
1,442 $101 $185
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
783 $139 $210
Injection, ranibizumab, 0.1 mg 509 $186 $420
Pegcetacoplan intravitreal injection, 1 mg
An injection of pegcetacoplan administered into the vitreous humor of the eye. The dose specified is 1 milligram.
330 $120 $200
Dexamethasone intravitreal implant injection
An injection of a dexamethasone implant placed inside the eye. This procedure delivers medication directly into the vitreous cavity of the eye.
245 $159 $215
Remote patient monitoring management, 20 min/month
Management based on results from remote vital sign monitoring for the first 20 minutes per calendar month.
162 $43 $150
Retinal angiography with dye injection
This procedure uses a special camera to examine the blood vessels in the retina after a dye has been injected into the body.
137 $124 $264
New patient office visit, complex (60-74 min) 136 $168 $250
Retinal photography (fundus photo)
This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures.
92 $30 $200
Unclassified drug
A medication that does not fit into standard HCPCS or CPT classification categories.
67 $1,978 $3,754
Compounded drug, not otherwise classified
A medication prepared specifically for an individual patient by a pharmacist or physician, tailored to meet unique needs that cannot be fulfilled by commercially available products.
61 $72 $180
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
25 $106 $185
Ultrasound of eye tissue and structures
A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures.
23 $42 $297
Multiple eye pressure measurements over time
This procedure involves taking several measurements of the fluid pressure inside the eye across an extended period. It is used to monitor intraocular pressure levels.
13 $72 $150
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$108,654
Total received (2018-2024)
Avg $15,522/year across 7 years
Top 4% in CA for ophthalmology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
40
Companies
608
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$44,171 (40.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$43,405 (39.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$21,078 (19.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$43,449
2023
$18,969
2022
$11,785
2021
$4,787
2020
$8,161
2019
$11,012
2018
$10,492

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Astellas Pharma US Inc
$20,252
Regeneron Healthcare Solutions, Inc.
$9,879
Genentech USA, Inc.
$8,089
US Oncology Corporate, Inc.
$2,226
Alcon Vision LLC
$1,009
ABBVIE INC.
$418
Apellis Pharmaceuticals, Inc.
$375
Alimera Sciences, Inc.
$273
Harrow Eye, LLC
$251
ANI Pharmaceuticals, Inc.
$193
Mallinckrodt Hospital Products Inc.
$145
Amgen Inc.
$137
Genentech, Inc.
$127
Sandoz Inc.
$32
Ocular Therapeutix, Inc.
$28
Biogen, Inc.
$16
Top 3 companies account for 88.0% of 2024 payments
All-time payments by company (2018-2024) ›
Regeneron Healthcare Solutions, Inc.
$41,936
Astellas Pharma US Inc
$23,294
Genentech USA, Inc.
$21,075
Alcon Vision LLC
$3,323
Novartis Pharmaceuticals Corporation
$2,543
US Oncology Corporate, Inc.
$2,226
Alimera Sciences, Inc.
$1,891
Allergan, Inc.
$1,700
Genentech, Inc.
$1,665
Alcon Laboratories Inc
$1,278
Apellis Pharmaceuticals, Inc.
$1,216
Mallinckrodt Hospital Products Inc.
$677
Allergan Inc.
$604
ABBVIE INC.
$580
Alcon Research Ltd
$490
Regeneron Pharmaceuticals, Inc.
$376
Oyster Point Pharma, Inc.
$358
Harrow Eye, LLC
$285
Aerie Pharmaceuticals, Inc.
$284
Horizon Therapeutics plc
$267
AbbVie Inc.
$263
OPTOS, INC.
$263
EyePoint Pharmaceuticals US, Inc.
$222
Biogen, Inc.
$194
ANI Pharmaceuticals, Inc.
$193
Shire North American Group Inc
$179
Notal Vision, Inc.
$175
Heidelberg Engineering, Inc.
$168
Amgen Inc.
$137
Coherus Biosciences Inc.
$127
Ocular Therapeutix, Inc.
$125
Sight Sciences, Inc.
$97
Bausch & Lomb Americas Inc.
$94
Bausch & Lomb, a division of Bausch Health US, LLC
$93
AbbVie, Inc.
$89
ThromboGenics, Inc.
$62
Optos, Inc.
$36
Sandoz Inc.
$32
Spark Therapeutics, Inc.
$19
Sun Pharmaceutical Industries Inc.
$17
Top 3 companies account for 79.4% of all-time payments
Associated products mentioned in payments ›
ACTHAR · BEOVU · BROMSITE · BYOOVIZ · COMBIGAN · Cimerli · Constellation · DEXTENZA · DEXYCU · DURYSTA · EYLEA · EYLEA AFLIBERCEPT INJECTION · EYLEA HD · Humira · IHEEZO · ILUVIEN · Iluvien · Izervay · Jetrea · LOTEMAX · LUMIGAN · LUXTURNA · Lucentis · Luxor · NGENUITY · Non-Covered Product · OCT OPHTHALMOSCOPE · OMNI(R) SURGICAL SYSTEM (US) · OZURDEX · P200DTx · PURIFIED CORTROPHIN GEL · RESTASIS MULTIDOSE · ReSure Sealant · SUSVIMO · Spectralis · Susvimo · Syfovre · TEPEZZA · TYRVAYA · VABYSMO · VEVYE · VISUDYNE · VUITY · VYZULTA · Vabysmo · XEN · XIIDRA · XIPERE · YUTIQ · ZYLET · rhopressa · rocklatan
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (41%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 4% for ophthalmology in CA.

Looking for an ophthalmology specialist in Santa Ana?
Compare ophthalmologists in the Santa Ana area by procedure volume, costs, and industry payment transparency.
Browse ophthalmologists nearby

Geographic Context

Ophthalmologists within 10 mi
409
Per 100K population
12.9
County median income
$113,702
Nearest hospital
ORANGE COUNTY GLOBAL MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Chen is a mixed practice specialist, with above-average Medicare volume (top 4% in CA), with consulting-driven industry engagement in the top 4% of CA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Chen experienced with eye injection (vabysmo/faricimab)?
Based on Medicare claims data, Dr. Chen performed 13,020 eye injection (vabysmo/faricimab) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chen receive payments from pharmaceutical companies?
Yes. Dr. Chen received a total of $108,654 from 40 companies across 608 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chen's costs compare to other ophthalmologists in Santa Ana?
Dr. Chen's average Medicare payment per service is $108. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chen) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →